A prospective study of clozapine in treatment-resistant schizophrenic patients. I. Preliminary report. 1989

H Y Meltzer, and B Bastani, and K Y Kwon, and L F Ramirez, and S Burnett, and J Sharpe
Department of Psychiatry, Case Western Reserve University School of Medicine, Cleveland, OH 44106.

Preliminary results of a non-blinded prospective study of the effect of clozapine on symptomatology and social function in 51 treatment-resistant schizophrenic patients are reported. The mean duration of treatment at the time of this report was 10.3 +/- 8.1 months, median 7.6 months. Overall, 3/51 patients (60.8%) showed at least a 20% decrease in total BPRS, a criterion of improvement in the study of Kane et al. (1988). Four of 51 (7.8%) had at least a 50% decrease in total BPRS. Improvements in both positive and negative symptoms were noted. Marked improvements in social function were noted within the first 6 months of treatment. Improvement was first noted at all time points, with only 45.2% of improvers being identified after 6 weeks of treatment. These results suggest a 6-12-month trial may be desirable before deciding to discontinue clozapine because of insufficient response. Higher total Brief Psychiatric Rating Scale (BPRS) score and higher ratings on the Paranoid Disturbance subscales of the BPRS were factors which discriminated clozapine responders from non-responders.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D011569 Psychiatric Status Rating Scales Standardized procedures utilizing rating scales or interview schedules carried out by health personnel for evaluating the degree of mental illness. Factor Construct Rating Scales (FCRS),Katz Adjustment Scales,Lorr's Inpatient Multidimensional Psychiatric Rating Scale,Wittenborn Scales,Edinburgh Postnatal Depression Scale,Mini International Neuropsychiatric Interview
D011788 Quality of Life A generic concept reflecting concern with the modification and enhancement of life attributes, e.g., physical, political, moral, social environment as well as health and disease. HRQOL,Health-Related Quality Of Life,Life Quality,Health Related Quality Of Life
D003024 Clozapine A tricylic dibenzodiazepine, classified as an atypical antipsychotic agent. It binds several types of central nervous system receptors, and displays a unique pharmacological profile. Clozapine is a serotonin antagonist, with strong binding to 5-HT 2A/2C receptor subtype. It also displays strong affinity to several dopaminergic receptors, but shows only weak antagonism at the dopamine D2 receptor, a receptor commonly thought to modulate neuroleptic activity. Agranulocytosis is a major adverse effect associated with administration of this agent. Clozaril,Leponex
D003984 Dibenzazepines Compounds with two BENZENE rings fused to AZEPINES.
D004351 Drug Resistance Diminished or failed response of an organism, disease or tissue to the intended effectiveness of a chemical or drug. It should be differentiated from DRUG TOLERANCE which is the progressive diminution of the susceptibility of a human or animal to the effects of a drug, as a result of continued administration. Resistance, Drug
D005260 Female Females

Related Publications

H Y Meltzer, and B Bastani, and K Y Kwon, and L F Ramirez, and S Burnett, and J Sharpe
January 1997, European psychiatry : the journal of the Association of European Psychiatrists,
H Y Meltzer, and B Bastani, and K Y Kwon, and L F Ramirez, and S Burnett, and J Sharpe
January 1997, European psychiatry : the journal of the Association of European Psychiatrists,
H Y Meltzer, and B Bastani, and K Y Kwon, and L F Ramirez, and S Burnett, and J Sharpe
August 1990, Hospital & community psychiatry,
H Y Meltzer, and B Bastani, and K Y Kwon, and L F Ramirez, and S Burnett, and J Sharpe
December 2007, Pakistan journal of biological sciences : PJBS,
H Y Meltzer, and B Bastani, and K Y Kwon, and L F Ramirez, and S Burnett, and J Sharpe
August 1993, The British journal of psychiatry : the journal of mental science,
H Y Meltzer, and B Bastani, and K Y Kwon, and L F Ramirez, and S Burnett, and J Sharpe
October 1998, The Journal of clinical psychiatry,
H Y Meltzer, and B Bastani, and K Y Kwon, and L F Ramirez, and S Burnett, and J Sharpe
December 1996, Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists,
H Y Meltzer, and B Bastani, and K Y Kwon, and L F Ramirez, and S Burnett, and J Sharpe
January 1997, The Journal of neuropsychiatry and clinical neurosciences,
H Y Meltzer, and B Bastani, and K Y Kwon, and L F Ramirez, and S Burnett, and J Sharpe
July 1999, Biological psychiatry,
H Y Meltzer, and B Bastani, and K Y Kwon, and L F Ramirez, and S Burnett, and J Sharpe
January 1993, Comprehensive psychiatry,
Copied contents to your clipboard!